Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,896 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study.
Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM. Stahl M, et al. Among authors: serrano j. Biol Blood Marrow Transplant. 2018 Aug;24(8):1754-1758. doi: 10.1016/j.bbmt.2018.03.025. Epub 2018 Apr 9. Biol Blood Marrow Transplant. 2018. PMID: 29649620 Free article.
A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia.
Bergua JM, Montesinos P, Martinez-Cuadrón D, Fernández-Abellán P, Serrano J, Sayas MJ, Prieto-Fernandez J, García R, García-Huerta AJ, Barrios M, Benavente C, Pérez-Encinas M, Simiele A, Rodríguez-Macias G, Herrera-Puente P, Rodríguez-Veiga R, Martínez-Sánchez MP, Amador-Barciela ML, Riaza-Grau R, Sanz MA; PETHEMA group. Bergua JM, et al. Among authors: serrano j. Br J Haematol. 2016 Sep;174(5):700-10. doi: 10.1111/bjh.14107. Epub 2016 Apr 26. Br J Haematol. 2016. PMID: 27118319 Free article.
A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups. Martínez-Cuadrón D, et al. Among authors: serrano j. Ann Hematol. 2018 May;97(5):763-772. doi: 10.1007/s00277-018-3229-5. Epub 2018 Feb 2. Ann Hematol. 2018. PMID: 29392425 Clinical Trial.
Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
Martínez-Cuadrón D, Boluda B, Martínez P, Bergua J, Rodríguez-Veiga R, Esteve J, Vives S, Serrano J, Vidriales B, Salamero O, Cordón L, Sempere A, Jiménez-Ubieto A, Prieto-Delgado J, Díaz-Beyá M, Garrido A, Benavente C, Pérez-Simón JA, Moscardó F, Sanz MA, Montesinos P; CETLAM and PETHEMA groups. Martínez-Cuadrón D, et al. Among authors: serrano j. Ann Hematol. 2018 May;97(5):923. doi: 10.1007/s00277-018-3277-x. Ann Hematol. 2018. PMID: 29473097 Free article.
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.
Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM. Stahl M, et al. Among authors: serrano j. Blood Adv. 2018 Apr 24;2(8):923-932. doi: 10.1182/bloodadvances.2018016121. Blood Adv. 2018. PMID: 29685952 Free PMC article.
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.
Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Stahl M, et al. Among authors: serrano j. Leuk Lymphoma. 2019 Jan;60(1):246-249. doi: 10.1080/10428194.2018.1468893. Epub 2018 Jul 2. Leuk Lymphoma. 2019. PMID: 29963936 Free article. No abstract available.
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
Martínez-Cuadrón D, Gil C, Serrano J, Rodríguez G, Pérez-Oteyza J, García-Boyero R, Jiménez-Bravo S, Vives S, Vidriales MB, Lavilla E, Pérez-Simón JA, Tormo M, Colorado M, Bergua J, López JA, Herrera P, Hernández-Campo P, Gorrochategui J, Primo D, Rojas JL, Villoria J, Moscardó F, Troconiz I, Linares Gómez M, Martínez-López J, Ballesteros J, Sanz M, Montesinos P; Spanish PETHEMA group. Martínez-Cuadrón D, et al. Among authors: serrano j. Leuk Res. 2019 Jan;76:1-10. doi: 10.1016/j.leukres.2018.11.006. Epub 2018 Nov 13. Leuk Res. 2019. PMID: 30468991 Free article.
Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients.
Rodríguez-Veiga R, Montesinos P, García E, Boluda B, Rojas R, Serrano J, Martínez-Cuadrón D, Martín C, Sanz J, Tabares S, Piñana JL, Lorenzo I, Montoro J, Salavert M, Pemán J, Jarque I, Solves P, Sanz GF, Torres A, Sanz MA. Rodríguez-Veiga R, et al. Among authors: serrano j. Mycoses. 2019 May;62(5):418-427. doi: 10.1111/myc.12891. Epub 2019 Mar 8. Mycoses. 2019. PMID: 30633829
Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia.
Megías-Vericat JE, Martínez-Cuadrón D, López JM, Bergua JM, Tormo M, Serrano J, González A, de Oteyza JP, Vives S, Vidriales B, Herrera P, Vera JA, Martínez AL, de la Fuente A, Amador ML, Hernández-Rivas JÁ, Fernández MÁ, Cerveró CJ, Morillo D, Campo PH, Gorrochategui J, Primo D, Rojas JL, Guenova M, Ballesteros J, Sanz M, Montesinos P. Megías-Vericat JE, et al. Among authors: serrano j. Mediterr J Hematol Infect Dis. 2019 Mar 1;11(1):e2019016. doi: 10.4084/MJHID.2019.016. eCollection 2019. Mediterr J Hematol Infect Dis. 2019. PMID: 30858954 Free PMC article.
Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group.
Ribera JM, García O, Moreno MJ, Barba P, García-Cadenas I, Mercadal S, Montesinos P, Barrios M, González-Campos J, Martínez-Carballeira D, Gil C, Ribera J, Vives S, Novo A, Cervera M, Serrano J, Lavilla E, Abella E, Tormo M, Amigo ML, Artola MT, Genescà E, Bravo P, García-Belmonte D, García-Guiñón A, Hernández-Rivas JM, Feliu E; PETHEMA Group of the Spanish Society of Hematology. Ribera JM, et al. Among authors: serrano j. Cancer. 2019 Aug 15;125(16):2810-2817. doi: 10.1002/cncr.32156. Epub 2019 Apr 23. Cancer. 2019. PMID: 31012967 Free article. Clinical Trial.
1,896 results